During his more than ten years at Cabot, Michael Cintolo has uncovered exceptional growth stocks and helped to create new tools and rules for buying and selling stocks. Perhaps most notable was his development of the proprietary trend-following market timing system, Cabot Tides, which has helped Cabot place among the top investment newsletters numerous times. Cabot Growth Investor has been consistently recognized for outstanding performance by Hulbert Financial Digest and Timer Digest. It is one of Hulbert's top five newsletters for five-year risk-adjusted performance with a 13.2% annualized return as of June 30, 2011. It is also ranked among the Top Ten Newsletters by Timer Digest for long-term performance.
Halozyme (HALO) has always had a story that’s easy to love, as its Enhanze drug delivery technology allows huge-selling treatments to be delivered intravenously in far less time than usual, saving tons of time, money and adding convenience, too, explains Mike Cintolo, editor of Cabot Growth Investor.
The past year has been a volatile one for asset managers like Affiliated Managers Group (AMG), which is a collection of hedge funds, including AQR, and mutual fund operators, like Tweedy Browne, explains Mike Cintolo, editor of Cabot Top Ten Trader.
The initial leaders in a broad energy sector advance are almost always the explorers, and the past couple of years proved no different, especially with the new playbook of limited CapEx, big dividends and big share buybacks, observes Mike Cintolo, editor of Cabot Growth Investor.
Clinical trials are essential to pharmaceutical companies seeking to bring new therapies to market since regulatory authorities want rigorous demonstration of a drug’s efficacy and safety, observes Mike Cintolo, editor of Cabot Top Ten Trader.